Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program

April 5, 2022

Join Christopher J. Moreau, CEO of Algernon Pharmaceuticals as he discusses investigating the psychedelic drug DMT as a new potential treatment for Stroke.

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company.

Sign up for our News Releases and Updates

Head Office

Suite 400 - 601 West Broadway
Vancouver, British Columbia V5Z 4C2

Follow Us On

© Algernon Pharmaceuticals - All Rights Reserved